Semaglutide for Smoking Cessation in Patients With Diabetes

Summary

To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.

Eligibility

Inclusion Criteria:

* Adults (18 years or older) with type 2 diabetes
* Currently residing in Ontario
* Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months
* Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.
* Have not used GLP-1 receptor agonists in the past six months.
* Able to provide informed consent

Exclusion Criteria:

* Pregnant or breastfeeding individuals
* Contraindication to NRT or GLP-1 RA.
* Current daily use of NRT or a GLP1 RA.
* Use of bupropion, cytisine, and varenicline within the last 7 days.
* Use of a DPP-IV inhibitor within the last 7 days.
* Initiation of a new diabetes medication within the last 3 months.
* As per the product monograph, participants with the following diagnoses or disorders will be excluded;
* Personal or family history of medullary thyroid cancer
* Personal or family history of Multiple Endocrine Neoplasia syndrome type 2
* Diabetic ketoacidosis
* Type I diabetes
* Acute pancreatitis or pancreatic cancer
* Acute, chronic or end-stage renal failure
* Tachyarrhythmias
* Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).
* Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).

Conditions4

Interventions2

Related trials

• A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver — Boehringer Ingelheim
• A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia — BrightGene Bio-Medical Technology Co., Ltd.
• A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) — Actimed Therapeutics Ltd
• A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus — Eli Lilly and Company
• COMMETS- Combination MCI Metabolic Syndrome — Rutgers, The State University of New Jersey
• Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes — Mostafa Bahaa
• GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM — Federico II University
• Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes — Steno Diabetes Center Copenhagen

Browse More Trials